Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Anti-seizure drugs could cause canine obesity, study finds
Dogs receiving ASD medication had a higher interest in food than healthy dogs.
Dogs taking the medication are more likely to have increased appetite.

New research has revealed that anti-seizure drugs (ASD) could be leading to more epileptic dogs becoming obese.

Researchers say that the drugs cause epileptic dogs to have an increased appetite which, when not properly managed, can cause weight issues. This risk is increased when dogs are given treats to help administer medication.

Dogs which suffer from idiopathic epilepsy are often prescribed ASD throughout their lifetimes. These drugs reduce the frequency and severity of the dog’s seizures, but rarely lead to seizure freedom.

The medication has a number of long-lasting side effects, including decreased energy, increased food intake and weight gain.

Though these side effects are widely published in veterinary literature, they have not previously been quantified or studied.

To analyse food motivation, researchers from the Royal Veterinary College (RVC) collaborated with the University of Cambridge to issue a validated Dog Obesity Risk Assessment questionnaire. The survey was designed to determine the link between ASDs and weight gain, as well as considering how caregivers manage weight gain.

The data compared 222 dogs that were diagnosed with idiopathic epilepsy with a control population of 7,086 healthy dogs.

Dogs which had idiopathic epilepsy and were receiving ASD were found to have a much higher food motivation than healthy dogs. They had increased interest in food, were less selective and were more interested in getting more food outside of meals.

Although their carers put effort into managing their pet’s diet, these dogs still had greater fat mass.

Fifty-three per cent of owners of dogs with epilepsy said they would always use treats to administer ASD medication, with 34 per cent saying they did not adjust their dog’s main food ration to suit. Since medication is usually administered twice a day, this can have a significant increase on calorie intake.

Rowena Packer, principal investigator of this research, said: “The findings of this research are key in helping the veterinary team provide greater information and support to pet owners managing their dog’s epilepsy.

“Although anti-seizure drugs are an essential part of the epilepsy treatment toolkit, ensuring owners are aware of the side effects and long-lasting impact of these medications is key in treatment decision-making, ensuring a balance between negative side effects such as increased food motivation against potential positive effects such as reduced seizure frequency, to maintain quality of life.”

The full study can be found in the journal Vet Record.

Image © Shutterstock

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.